Resona Asset Management Co. Ltd. Has $58.67 Million Stake in Gilead Sciences, Inc. $GILD

Posted by Brian Himes on Jul 9th, 2026

Gilead Sciences logo Resona Asset Management Co. Ltd. raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.1% in the 1st quarter, Holdings Channel reports. The firm owned 422,586 shares of the biopharmaceutical company’s stock after purchasing an additional 8,508 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Gilead Sciences were worth $58,667,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC raised its position in shares of Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares during the last quarter. Quattro Advisors LLC bought a new position in shares of Gilead Sciences during the fourth quarter worth about $26,000. Wealth Preservation Advisors LLC lifted its stake in shares of Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares during the period. Finally, Ares Financial Consulting LLC acquired a new position in shares of Gilead Sciences in the fourth quarter worth approximately $28,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Down 0.4%

Shares of Gilead Sciences stock opened at $135.82 on Thursday. The stock’s 50-day moving average is $129.64 and its 200 day moving average is $134.92. Gilead Sciences, Inc. has a one year low of $107.75 and a one year high of $157.29. The firm has a market cap of $168.63 billion, a price-to-earnings ratio of 18.50 and a beta of 0.32. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the previous year, the company posted $1.81 earnings per share. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post -0.81 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were paid a $0.82 dividend. The ex-dividend date was Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. Gilead Sciences’s payout ratio is currently 44.69%.

Analyst Ratings Changes

A number of analysts have weighed in on GILD shares. Royal Bank Of Canada decreased their target price on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a research report on Tuesday. The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research report on Friday, April 17th. Truist Financial reduced their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research note on Tuesday. Daiwa Securities Group decreased their price objective on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, May 19th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 target price on shares of Gilead Sciences in a research note on Monday. Twenty-six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $159.04.

View Our Latest Report on GILD

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the completion of the sale, the insider directly owned 124,234 shares of the company’s stock, valued at approximately $15,395,077.28. This trade represents a 2.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,000 shares of company stock worth $10,824,500 in the last quarter. 0.30% of the stock is owned by corporate insiders.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.